[go: up one dir, main page]

Huszno et al., 2016 - Google Patents

A comparison between CHEK2* 1100delC/I157T mutation carrier and noncarrier breast cancer patients: A clinicopathological analysis

Huszno et al., 2016

Document ID
17353720307731304964
Author
Huszno J
Budryk M
Kołosza Z
Tęcza K
Pamuła Piłat J
Nowara E
Grzybowska E
Publication year
Publication venue
Oncology

External Links

Snippet

Objective: The suppressor gene CHEK2 encodes a cell cycle checkpoint kinase, involved in cell cycle regulation, apoptosis and response to DNA damage. The aim of this study was to analyze the differences between CHEK2 mutation carriers (CHEK2* 1100delC/I157T) and …
Continue reading at karger.com (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Similar Documents

Publication Publication Date Title
Zarkavelis et al. Current and future biomarkers in colorectal cancer
Sini et al. Genetic alterations in main candidate genes during melanoma progression
Georgitsi MEN-4 and other multiple endocrine neoplasias due to cyclin-dependent kinase inhibitors (p27Kip1 and p18INK4C) mutations
Roldán et al. Tumoral expression of BRCA1, estrogen receptor alpha and ID4 protein in patients with sporadic breast cancer
Huszno et al. A comparison between CHEK2* 1100delC/I157T mutation carrier and noncarrier breast cancer patients: A clinicopathological analysis
Gallenne et al. Systematic functional perturbations uncover a prognostic genetic network driving human breast cancer
Bravatà et al. Genotyping analysis and 18FDG uptake in breast cancer patients: a preliminary research
KR20150028232A (en) Breast cancer prognosis, prediction of progesterone receptor subtype and prediction of response to antiprogestin treatment based on gene expression
Frank et al. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer
Romanowicz‐Makowska et al. Single nucleotide polymorphisms of RAD51 G135C, XRCC2 Arg188His and XRCC3 Thr241Met homologous recombination repair genes and the risk of sporadic endometrial cancer in Polish women
Kang et al. Mutant TP53 G245C and R273H promote cellular malignancy in esophageal squamous cell carcinoma
Khoo et al. Somatic mutations in salivary duct carcinoma and potential therapeutic targets
Lurje et al. Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma
Glubb et al. Functional FLT1 genetic variation is a prognostic factor for recurrence in stage I–III non–small-cell lung cancer
Kucera et al. Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node-and steroid receptor positive breast cancer patients
Berardi et al. Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy
Rahmy et al. Organ-specific regulation of CHD1 by acute PTEN and p53 loss in mice
Mikse et al. The impact of the MYB-NFIB fusion proto-oncogene in vivo
Sallinen et al. CHEK2 mutations in primary glioblastomas
Chen et al. Genomic landscape of secretory carcinoma of the breast with axillary lymph node metastasis
Karam et al. Upregulation of TRAG3 gene in urothelial carcinoma of the bladder
Nilforoushan et al. Evaluation of MTAP immunohistochemistry loss of expression in ovarian serous borderline tumors as a potential marker for prognosis and progression
US9074259B2 (en) Use of genetic modifications in human gene CHK1 which codes for checkpoint kinase 1
An et al. Association between SNPs in Wnt signaling pathway genes and ovarian cancer risk in Northern Chinese population.
Fedko et al. Clinical and Morphological Features of g PALB2-Associated Breast Cancer in the Russian Population